SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2017 / Cilt: 47 - Sayı: 6

Plasma urotensin II levels in primary Raynaud's phenomenon and systemic sclerosis

Burak ÖZ
Faruk KILINÇ
Ramazan ULU
Süleyman AYDIN
Süleyman Serdar KOCA
Ahmet KARATAŞ
Mesude Seda KINACI
Nevzat GÖZEL
Emir DÖNDER
Fatih DEMİRCAN
Meltem YARDIM
Pages
1687–1692
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, it can be concluded that decreased UII level is related to SSc instead of RP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The pathogenesis of Raynaud s phenomenon (RP) has not yet been fully elucidated.
📊
Key Findings & Data:RP is characterized by exaggerated cold-induced vasoconstriction.
💡
Conclusion & Impact:Therefore, it can be concluded that decreased UII level is related to SSc instead of RP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: The pathogenesis of Raynaud s phenomenon (RP) has not yet been fully elucidated. RP is characterized by exaggerated cold-induced vasoconstriction. Urotensin II (UII) is a potent vasoconstrictor. The aim of the present study was to evaluate plasma UII levels in both primary RP and secondary RP associated with systemic sclerosis (SSc). Materials and methods: Fifteen patients with primary RP, 30 patients with RP secondary to SSc, and 30 healthy controls (HC) were included in the study. Raynaud condition scores (RCS) were determined in the primary RP and SSc groups. Modified Rodnan skin score (MRSS) was determined for the SSc patients. Plasma UII level was analyzed by the ELISA method. Results: When compared to the HC group, plasma UII level was lower in the secondary RP group, but not in the primary RP group. Plasma UII level was not directly related to RCS in either the primary or secondary RP group. Moreover, it was not correlated with MRSS in the secondary RP group. Conclusion: The results of the present study suggest that UII is not associated with primary RP. Its level was lower in the secondary RP (SSc) patients. Therefore, it can be concluded that decreased UII level is related to SSc instead of RP.

🔖

Cite This Article

ÖZ, B., KILINÇ, F., ULU, R., AYDIN, S., KOCA, S. S., KARATAŞ, A., KINACI, M. S., GÖZEL, N., DÖNDER, E., DEMİRCAN, F., YARDIM, M. (2022). Plasma urotensin II levels in primary Raynaud's phenomenon and systemic sclerosis. Turkish Journal of Medical Sciences, Cilt: 47 - Sayı: 6, 1687–1692. https://ajindex.com/articles/610479

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol 2005; 17: 752- 760
  2. Wigley FM. Clinical practice. Raynaud’s phenomenon. N Engl J Med 2002; 347: 1001-1008
  3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142
  4. Zamora MR, O’Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud’s phenomenon. Lancet 1990; 336: 1144-1147
  5. Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 2015; 67: 214-258
  6. Peng H, Zhang M, Cai X, Olofindayo J, Tan A, Zhang Y. Association between human urotensin II and essential hypertension-a 1:1 matched case-control study. PLoS One 2013; 8: e81764
  7. Buyukhatipoglu H, Buyukaslan H, Pehlivan Y, Ceylan N, Ulas T, Tarakcioglu M, Onat AM. Increased urotensin-II activity in patients with Raynaud’s phenomenon and systemic lupus erythematosus. Int J Rheum Dis 2011; 143: 276-281
  8. LeRoy EC, Medsger TA Jr. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485-488
  9. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-1755
  10. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002; 46: 2410-2420
  11. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D. Course of modified Rodnan skin score in systemic sclerosis clinical trials: analysis of 3 large multicenter, randomized clinical trials. Arthritis Rheum 2009; 60: 2490-2498
  12. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131: 441-446
  13. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. C